Ultragenyx reports Q4 EPS ($1.39), consensus ($1.27)
Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...
Goldman Sachs maintains buy on Ultragenyx, target at $78
Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...
Year-end Report - January-December 2024
Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. “Stronger liquidity will ensure our ...
Cantor Fitzgerald maintains $118 target on Ultragenyx stock
Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...
manilatimes18h
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Total operating expenses for the fourth quarter of 2024 were $287 million, including non-cash stock-based compensation of $40 ...
Q4 2024 Ultragenyx Pharmaceutical Inc Earnings Call
Emil Kakkis; President, Chief Executive Officer, Director; Ultragenyx Pharmaceutical Inc Erik Harris; Executive Vice President, Chief Commercial Officer; Ultragenyx Pharmaceutical Inc Howard Horn; ...
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2024 Earnings Call Transcript
Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode. At the end of the prepared ...